The consumer technology industry is increasingly asking buyers to pay twice: once for the device, and again for the software features that make it useful. Four stories logged on this desk in the past two days, spanning AI acquisitions, smart glasses, medical devices and smart home cameras, all point to the same underlying shift. Hardware margins are being protected not by selling better boxes, but by attaching recurring revenue to them.
Apple Puts Home Intelligence Behind a Paywall
The clearest example comes from Apple. As The Verge reported, the public release of iOS 27 and tvOS 27 brings Apple Intelligence features to Apple Home, including AI-powered video summaries for HomeKit Secure Video that generate short text descriptions of who and what compatible security cameras saw. Those features cost up to $60 a month. It is a notable move for a company that has historically bundled software updates into the hardware purchase. The camera itself still works, but the intelligence layered on top is now a subscription product, and the monthly ceiling is steep enough that it rivals standalone security services. For US consumers who bought into Apple's smart home ecosystem on the promise of seamless integration, the calculus has changed. The hardware is the entry ticket; the useful part is metered.
OpenAI Buys Its Way Into the Camera
On the same day, TechCrunch reported that OpenAI is acquiring smartphone camera maker Glass Imaging for $300 million. Glass Imaging was founded by two former Apple engineers who previously led the team behind Apple's Portrait Mode. The deal is a reminder that the most valuable camera improvements in modern phones are computational, not optical, and that the software layer is where differentiation now lives. OpenAI is not a hardware company in the traditional sense, but it is buying the expertise that turns sensor data into images people want. The pattern here is subtler than a subscription, but related: value is migrating away from the physical component and toward the algorithm that interprets it. Whoever owns the algorithm owns the upgrade path, and can decide what is included and what is charged for later.
A $2,200 Medical Device With No Subscription
Flow Neuroscience offers a counterexample worth noting. As Wired reported, the company's headset for depression is now available in the US, approved by the FDA, and could help people get off antidepressants. It costs $2,200. There is no reported monthly fee. But the price point itself tells the story. This is a device that sits at the boundary between consumer gadget and medical equipment, and it is priced accordingly. For US consumers, the question is whether insurers will ever treat it as a covered treatment rather than an out-of-pocket curiosity. The absence of a subscription does not make it cheap; it simply front-loads the cost. The broader lesson is that when hardware is genuinely differentiated and regulated, companies can still charge a premium upfront. When it is not, they increasingly reach for recurring revenue.
